Cambridge-based Lantos Technologies, developers of the first ever intra-aural 3D scanner, announced that it has closed $4.1 million in a Series B financing round led by Catalyst Health Ventures, Excel Venture Management and Mass Medical Angels. In addition to raising additional capital, Lantos Technologies named Jeffery Leathe as Chief Executive Officer and Chairman of the Company’s Board of Directors.
The company will use the funding to further develop the real-time 3D ear canal scanning technology that will allow a more customized fit for audio devices like hearing aids and earphones. The technology gives an accurate and digital mapping of your human ear canal in order to find the best fit for these types of devices.
“We are delighted to have Jeff join the Lantos team at such an exciting time in the Company’s development. Jeff brings to Lantos tremendous knowledge and experience in building successful companies and is uniquely qualified to lead Lantos as it prepares to commercialize its proprietary technology”, said Darshana Zaveri, Partner, Catalyst Health Ventures
Mr. Leathe previously served as Chairman and CEO of Biocius Life Sciences, a company that focused on drug discovery research and clinical diagnostic testing. Before that, he served as a senior executive at BioTrove, a genomics products company, and as Executive Vice President of Apogent Technologies, a life science research and clinical diagnostics company, respectively.
Mr Leathe had this to say about joining Lantos Technologies: “I am excited to be joining the Lantos team as the company prepares for clinical trials and regulatory filings in advance of its first product launch expected in 2012. Intra-aural scanning is seen as the holy grail of audiology and with the Lantos technology, team and additional funding, this dream is becoming closer to reality for the industry.”
Back in September 2010, Lantos Technologies closed their Series A Financing totaling $1.6 million. Catalyst Health Ventures led the series A, while Excel Venture Management and Mass Medical Angels contributed, as well. The original technology was developed in a lab by MIT professor Douglas Hart.
